Limits...
Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.

Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G - Eur. Heart J. (2015)

Bottom Line: There is an unmet need for new therapy options with new drugs with a new mode of action.One of the drugs currently in clinical testing in Phase III is ularitide, which is the chemically synthesized form of the human natriuretic peptide urodilatin.In animal models of heart failure as well as Phase I and II clinical studies in heart failure patients, ularitide demonstrated beneficial effects such as symptom relief and vasodilation, while still preserving renal function.

View Article: PubMed Central - PubMed

Affiliation: Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany s.anker@cachexia.de.

Show MeSH

Related in: MedlinePlus

(A) Summarized patients' dyspnoea assessments of ‘moderately improved’ or ‘markedly improved’ at 6 and 24 h. P values of tests vs. placebo, considering all scores (Uleman test). (B) Mean (standard deviation) change from baseline in pulmonary capillary wedge pressure (ΔPCWP) at 6 h in pooled ularitide- and placebo-treated patients who assessed dyspnoea as ‘no change’, ‘minimally improved’, ‘moderately improved’, or ‘markedly improved’.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4368857&req=5

EHU484F5: (A) Summarized patients' dyspnoea assessments of ‘moderately improved’ or ‘markedly improved’ at 6 and 24 h. P values of tests vs. placebo, considering all scores (Uleman test). (B) Mean (standard deviation) change from baseline in pulmonary capillary wedge pressure (ΔPCWP) at 6 h in pooled ularitide- and placebo-treated patients who assessed dyspnoea as ‘no change’, ‘minimally improved’, ‘moderately improved’, or ‘markedly improved’.

Mentions: In the ularitide groups, more patients assessed their dyspnoea as moderately or markedly improved (Figure 5A), whereas in the placebo group, patients most frequently reported no change. The gradual decrease of PCWP at 6 h correlated well with pooled ularitide- and placebo-treated patients' dyspnoea assessments (Figure 5B).Figure 5


Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.

Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G - Eur. Heart J. (2015)

(A) Summarized patients' dyspnoea assessments of ‘moderately improved’ or ‘markedly improved’ at 6 and 24 h. P values of tests vs. placebo, considering all scores (Uleman test). (B) Mean (standard deviation) change from baseline in pulmonary capillary wedge pressure (ΔPCWP) at 6 h in pooled ularitide- and placebo-treated patients who assessed dyspnoea as ‘no change’, ‘minimally improved’, ‘moderately improved’, or ‘markedly improved’.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4368857&req=5

EHU484F5: (A) Summarized patients' dyspnoea assessments of ‘moderately improved’ or ‘markedly improved’ at 6 and 24 h. P values of tests vs. placebo, considering all scores (Uleman test). (B) Mean (standard deviation) change from baseline in pulmonary capillary wedge pressure (ΔPCWP) at 6 h in pooled ularitide- and placebo-treated patients who assessed dyspnoea as ‘no change’, ‘minimally improved’, ‘moderately improved’, or ‘markedly improved’.
Mentions: In the ularitide groups, more patients assessed their dyspnoea as moderately or markedly improved (Figure 5A), whereas in the placebo group, patients most frequently reported no change. The gradual decrease of PCWP at 6 h correlated well with pooled ularitide- and placebo-treated patients' dyspnoea assessments (Figure 5B).Figure 5

Bottom Line: There is an unmet need for new therapy options with new drugs with a new mode of action.One of the drugs currently in clinical testing in Phase III is ularitide, which is the chemically synthesized form of the human natriuretic peptide urodilatin.In animal models of heart failure as well as Phase I and II clinical studies in heart failure patients, ularitide demonstrated beneficial effects such as symptom relief and vasodilation, while still preserving renal function.

View Article: PubMed Central - PubMed

Affiliation: Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany s.anker@cachexia.de.

Show MeSH
Related in: MedlinePlus